NEWS & MEDIA

PRESS RELEASES NEWS & PERSPECTIVES EXPERT PERSPECTIVES MEDIA RESOURCES

PRESS RELEASES

04-10-2024

Kura Oncology to Participate in Stifel Targeted Oncology Forum

04-05-2024

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03-06-2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

VIEW ALL

NEWS & PERSPECTIVES

Life at Kura

Kura Core Values

Media Coverage

Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

Media Coverage

Kura Oncology Reports Preliminary Data From Menin Inhibitor, Chemo Combination Trial in AML

Media Coverage

Kura’s Leukemia Treatment Performs Best When Tacked Onto Existing Combo, New Data Show

Media Coverage

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

Media Coverage

PharmaVoice’s Crystal Ball: Perspectives on the financial future

Media Coverage

Kathy Ford, R.N., B.S.N., Kura COO, on Ordinarily Extraordinary – Conversations with Women in STEM podcast

Media Coverage

Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place

Media Coverage

The Promise of Precision Oncology, Troy Wilson, President & CEO, Kura Oncology

Awards

SDUT San Diego Top Workplaces 2023

Media Coverage

Kura Oncology’s CEO gives an update on Q3 earnings

Awards

2023 Scrip Awards Best Oncology R&D Advance

Awards

2023 Scrip Awards Executive of the Year – Developmental Stage Companies: Stephen Dale, M.D.

Awards

PharmaVoice 100 Top Industry Leaders: Teresa Bair, J.D.

Kura Kommentary

CEO Troy Wilson On Giving Back: Empowering Young Minds to Explore Life Sciences

Awards

San Diego Business Journal Leaders of Influence in Life Science 2023 Honorees

Awards

San Diego Business Journal CEO of the Year Awards 2023 Finalists

Kura Kommentary

World Medical Innovation Forum Panel on The Innovation Gap: The Promise of Precision Oncology for Liquid Tumors

Kura Kommentary

What pharma can teach biotech about the life cycle management of a drug

Kura Kommentary

Kura Oncology 2022 Annual Report

Awards

The Medicine Maker Power List 2023: Francis Burrows

Life at Kura

The History and Culture of Kura

Media Coverage

Navigating Dose Optimization Requirements as a Small Biotech

Awards

SDUT San Diego Top Workplaces 2022

Awards

PharmaVoice 100 Innovators: Dr. Stephen Dale

Media Coverage

Liquid Biopsies Guide the Development of Cancer Drugs

Life at Kura

COO Kathy Ford on What Makes Kura a Top Workplace

Awards

SDUT San Diego Top Workplaces 2021

Media Coverage

FDA’s Renewed Focus on Oncology Dosing Spooks Investors, but Companies Say They’re Ready

Media Coverage

Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC with HRAS Mutations

Media Coverage

Is This the Dawn of Precision Oncology in Head and Neck Cancer?

Kura Kommentary

CEO Troy Wilson on Sailing Through the Storm: Lessons from the Pandemic

Awards

PharmaVoice 100: Innovator’s Journey

Awards

PharmaVoice 100: Entrepreneurs

Media Coverage

BIO: Kura Oncology CEO Wilson on the power of biotech in the quest beyond KRAS

Kura Kommentary

CEO Troy Wilson on Navigating a Clinical Stage Biopharmaceutical Company Through the Pandemic

EXPERT PERSPECTIVES ON AML AND ZIFTOMENIB CLINICAL TRIALS

Harry Erba, MD, PhD

Dr. Erba discusses the KOMET-001 Phase 1b safety and tolerability data of ziftomenib, a menin inhibitor, for patients with R/R NPM1-m AML

December 20, 2023/in Erba, videos

Dr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML

December 19, 2023/in Erba, videos

Dr. Erba explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007

December 18, 2023/in Erba, videos

“Project Optimus encourages optimal biological dosing rather than maximally tolerated dosing.” — Harry Erba, MD, PhD

December 17, 2023/in Erba, videos

Dr. Erba provides an overview of the KOMET clinical trial program

December 16, 2023/in Erba, videos

Dr. Fathi presents the latest KOMET-001 data

September 19, 2023/in Fathi, videos

NPM1 mutations in acute myeloid leukemia: actionable mutations to inform treatment decisions with clinical trials

August 8, 2023/in Fathi, videos

Mechanism of action for investigational menin inhibitors, including ziftomenib

August 8, 2023/in Fathi, videos

Can you give a brief overview of unmet medical needs within NPM1-mutated acute myeloid leukemia?

June 16, 2023/in Fathi, videos

Emerging advancements in acute myeloid leukemia

June 16, 2023/in Fathi, videos

Evaluating ziftomenib in combinations for patients who are newly diagnosed or relapsed/refractory NPM1m or KMT2Ar AML

August 23, 2023/in videos, Zeidan

MEDIA RESOURCES

Essential assets such as logos and images related to Kura Oncology.

VIEW ALL

NEWS & MEDIA

PRESS RELEASES

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

NEWS & PERSPECTIVES

Year:

Type:

Kura Core Values

Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

Kura Oncology Reports Preliminary Data From Menin Inhibitor, Chemo Combination Trial in AML

Kura’s Leukemia Treatment Performs Best When Tacked Onto Existing Combo, New Data Show

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

PharmaVoice’s Crystal Ball: Perspectives on the financial future

Kathy Ford, R.N., B.S.N., Kura COO, on Ordinarily Extraordinary – Conversations with Women in STEM podcast

Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place

The Promise of Precision Oncology, Troy Wilson, President & CEO, Kura Oncology

SDUT San Diego Top Workplaces 2023

Kura Oncology’s CEO gives an update on Q3 earnings

2023 Scrip Awards Best Oncology R&D Advance

2023 Scrip Awards Executive of the Year – Developmental Stage Companies: Stephen Dale, M.D.

PharmaVoice 100 Top Industry Leaders: Teresa Bair, J.D.

CEO Troy Wilson On Giving Back: Empowering Young Minds to Explore Life Sciences

San Diego Business Journal Leaders of Influence in Life Science 2023 Honorees

San Diego Business Journal CEO of the Year Awards 2023 Finalists

World Medical Innovation Forum Panel on The Innovation Gap: The Promise of Precision Oncology for Liquid Tumors

What pharma can teach biotech about the life cycle management of a drug

Kura Oncology 2022 Annual Report

The Medicine Maker Power List 2023: Francis Burrows

The History and Culture of Kura

Navigating Dose Optimization Requirements as a Small Biotech

SDUT San Diego Top Workplaces 2022

PharmaVoice 100 Innovators: Dr. Stephen Dale

Liquid Biopsies Guide the Development of Cancer Drugs

COO Kathy Ford on What Makes Kura a Top Workplace

SDUT San Diego Top Workplaces 2021

FDA’s Renewed Focus on Oncology Dosing Spooks Investors, but Companies Say They’re Ready

Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC with HRAS Mutations

Is This the Dawn of Precision Oncology in Head and Neck Cancer?

CEO Troy Wilson on Sailing Through the Storm: Lessons from the Pandemic

PharmaVoice 100: Innovator’s Journey

PharmaVoice 100: Entrepreneurs

BIO: Kura Oncology CEO Wilson on the power of biotech in the quest beyond KRAS

CEO Troy Wilson on Navigating a Clinical Stage Biopharmaceutical Company Through the Pandemic

EXPERT PERSPECTIVES ON AML AND ZIFTOMENIB CLINICAL TRIALS

Harry Erba, MD, PhD

Amir T. Fathi, MD

Amer Zeidan, MBBS, MHS

MEDIA RESOURCES